Clearside Biomedical(CLSD) - 2025 Q1 - Quarterly Results

Clearside Biomedical Q1 2025 Earnings Release Corporate Update and Program Highlights Clearside Biomedical advanced CLS-AX to Phase 3, saw partner milestones, and featured its SCS Microinjector® platform in over 15 presentations - Reached alignment with the FDA on the Phase 3 program design for CLS-AX in wet AMD, targeting a flexible three-to-six-month maintenance dosing schedule, which is believed to offer a commercially compelling product profile[1][2][6] - Development partner BioCryst Pharmaceuticals received authorization to initiate its first clinical trial in Australia for avoralstat for Diabetic Macular Edema (DME), with initial data expected in 2025[2][6] - Asia-Pacific partner Arctic Vision's New Drug Application (NDA) for ARCATUS® was accepted for review in China and approved in both Australia and Singapore for the treatment of uveitic macular edema (UME)[2][6] - The company's suprachoroidal drug delivery platform was featured in over 15 presentations at major ophthalmic medical meetings, including ARVO 2025, indicating growing interest in the technology[1][6] First Quarter 2025 Financial Results Clearside reported increased Q1 2025 revenue to $2.3 million, reduced net loss to $8.2 million, and maintained $13.6 million in cash, funding operations into Q4 2025 Q1 2025 Statement of Operations Highlights (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | License and other revenue | $2,330 | $230 | | Research and development | $4,463 | $5,615 | | General and administrative | $2,824 | $2,824 | | Loss from operations | ($5,205) | ($8,209) | | Net loss | ($8,223) | ($11,763) | | Net loss per share | ($0.11) | ($0.17) | - The increase in revenue was primarily attributable to $1.5 million in milestones from partner Arctic Vision and $0.8 million in other revenue for training, services, and sales of SCS Microinjector kits[6] - The decrease in R&D expenses was primarily due to lower clinical trial costs following the completion of the ODYSSEY Phase 2b trial[6] Balance Sheet Summary (in thousands) | Balance Sheet Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $13,628 | $20,020 | | Total assets | $19,668 | $25,126 | | Total liabilities | $65,578 | $63,981 | - As of March 31, 2025, cash and cash equivalents totaled $13.6 million. The company believes it has sufficient resources to fund planned operations into the fourth quarter of 2025[9]